Electromed (NYSE:ELMD) is a medical technology company specializing in the development, manufacturing and distribution of respiratory support and diagnostic systems. The company’s flagship offering, the The Vest® Airway Clearance System, employs High Frequency Chest Wall Oscillation (HFCWO) therapy to assist patients in clearing mucus from their lungs. In addition to its core respiratory care products, Electromed provides a suite of diagnostic monitoring and biofeedback devices designed to complement its therapeutic portfolio and support clinicians in optimizing patient outcomes.
Founded in 1990 and headquartered in Cleveland, Ohio, Electromed has grown from a single-product enterprise to a diversified medical device manufacturer. Over the decades, the company has expanded its product pipeline through both in-house research and strategic collaborations with academic institutions and clinical centers. Electromed’s manufacturing operations adhere to rigorous quality standards, including FDA and ISO certifications, ensuring that its devices meet stringent safety and efficacy requirements.
Electromed’s market presence spans North America, Europe and select Asia-Pacific regions. The company leverages a combination of direct sales teams, contracted distributors and strategic partnerships to serve hospitals, outpatient clinics and home healthcare providers. By tailoring its sales and marketing initiatives to regional regulatory landscapes and reimbursement environments, Electromed aims to facilitate broader patient access to its respiratory care solutions.
Guided by an experienced management team with deep expertise in medical device innovation, regulatory affairs and reimbursement strategy, Electromed continues to invest in research and development. The company’s leadership emphasizes collaboration with healthcare professionals and patient advocacy groups to refine existing technologies and explore new applications for airway clearance therapy. Electromed remains committed to advancing respiratory health through ongoing product enhancements and a focus on evidence-based care.
